PSTV News and Press, PLUS THERAPEUTICS Inc. From 10/20/22

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186 RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical trials for ...

Plus Therapeutics ( NASDAQ: PSTV ) is scheduled to announce Q3 earnings results on Thursday, October 20th, after market close. The consensus EPS estimate is -$0.21 . Over the last 3 months, EPS estimates have seen 0 upward revision and 2 downward revisions. F...

ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts ReSPECT-GBM Phase 1 clinical data selected as Top-Rated Oral Pres...

AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief ...

Cheap Penny Stocks To Buy Penny stocks generally trade for $5 per share, which makes them some of the most appealing for new or novice traders. The ability to purchase hundreds, thousands, or even millions of shares for a couple of hundred dollars gives way to scoring big when stocks ex...

Nano-cap biotech Plus Therapeutics ( NASDAQ: PSTV ) gained ~18% pre-market Friday on rising volumes after financial brokerage JonesTrading started its coverage with a Buy rating on the potential of the company’s lead asset Rhenium-186 NanoLiposome. 1.6M PSTV sha...

AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will ...

AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Dr. Andrew ...

AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will ...

Plus Therapeutics ( NASDAQ: PSTV ) on Thursday said it finalized and signed a previously announced $17.6M grant contract that had it received from a Texas institute, and that the initial funds of $1.9M from the grant would be disbursed to the company by Oct. 31. Shares...